|
|
Screening for Fabry disease and Hereditary ATTR amyloidosis in idiopathic small-fiber and mixed neuropathy |
|---|---|
| Author: | Samuelsson, Kristin1; Radovic, Ana2; Press, Rayomand1; |
| Organizations: |
1Department of Clinical Neuroscience, Karolinska Institute, R54, Huddinge, 141 86 Stockholm, Sweden 2Department of Neurology, Karolinska University Hospital, Stockholm, Sweden 3Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland
4Research Unit of Clinical Neuroscience, Neurology, University of Oulu, Oulu, Finland
5Department of Neurology, Tampere University Hospital and Faculty of Medical and Life Sciences, University of Tampere, Tampere, Finland 6Department of Neurology, University Hospital of North Norway, Tromsø, Norway 7Department of Neurology, Sørlandet Hospital, Kristiansand, Norway 8Department of Neurology, Oslo University Hospital and Faculty of Medicine, University of Oslo, Oslo, Norway 9Department of Neurology, Aarhus University Hospital, Aarhus, Denmark |
| Format: | article |
| Version: | accepted version |
| Access: | open |
| Online Access: | PDF Full Text (PDF, 1.3 MB) |
| Persistent link: | http://urn.fi/urn:nbn:fi-fe2019070922896 |
| Language: | English |
| Published: |
John Wiley & Sons,
2019
|
| Publish Date: | 2020-03-31 |
| Description: |
AbstractIntroduction: In this study we assessed the value of genetic screening for Fabry disease (FD) and hereditary ATTR amyloidosis in patients with idiopathic small‐fiber neuropathy (SFN) or mixed neuropathy in a clinical setting. Methods: This was a Nordic multicenter study with 9 participating centers. Patients with idiopathic SFN or mixed neuropathy were included. Genetic sequencing of the TTR and GLA genes was performed. Results: There were 172 patients enrolled in the study. Genetic screening was performed in 155 patients. No pathogenic mutations in the TTR gene were found. A single patient had a possible pathogenic variant, R118C, in the GLA gene, but clinical investigation showed no firm signs of FD. Discussion: Screening for hereditary ATTR amyloidosis and FD in patients with idiopathic SFN or mixed neuropathy without any additional disease‐specific symptoms or clinical characteristics in a Nordic population appears to be of little value in a clinical setting. see all
|
| Series: |
Muscle & nerve |
| ISSN: | 0148-639X |
| ISSN-E: | 1097-4598 |
| ISSN-L: | 0148-639X |
| Volume: | 59 |
| Issue: | 3 |
| Pages: | 354 - 357 |
| DOI: | 10.1002/mus.26348 |
| OADOI: | https://oadoi.org/10.1002/mus.26348 |
| Type of Publication: |
A1 Journal article – refereed |
| Field of Science: |
3124 Neurology and psychiatry |
| Subjects: | |
| Copyright information: |
© 2018 Wiley Periodicals, Inc. This is the peer reviewed version of the following article: Samuelsson, K. , Radovic, A. , Press, R. , Auranen, M. , Ylikallio, E. , Tyynismaa, H. , KäRppä, M. , Veteläinen, M. , Peltola, N. , Mellgren, S. I., Mygland, Å. , Tallaksen, C. , Andersen, H. , Terkelsen, A. J., Fontain, F. and Hietaharju, A. (2019), Screening for Fabry disease and Hereditary ATTR amyloidosis in idiopathic small‐fiber and mixed neuropathy. Muscle Nerve, 59: 354-357. doi:10.1002/mus.26348, which has been published in final form at https://doi.org/10.1002/mus.26348. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. |